Wordt geladen...
Phase 3, Randomized Controlled Trial of Atrasentan in Patients with Nonmetastatic Hormone-Refractory Prostate Cancer
BACKGROUND: Atrasentan is a potent, oral, selective endothelin-A (ET(A)) receptor antagonist with clinical activity in patients with hormone-refractory prostate cancer (HRPC). This reports the results of a Phase 3, randomized, double-blind, placebo-controlled trial of atrasentan in patients with non...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2008
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3085548/ https://ncbi.nlm.nih.gov/pubmed/18785254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23864 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|